Загрузка...
Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
BACKGROUND: Uncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (P...
Сохранить в:
| Опубликовано в: : | Radiol Oncol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Sciendo
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6287173/ https://ncbi.nlm.nih.gov/pubmed/30367809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2018-0037 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|